Design and optimization of pantoprazole sodium mucoadhesive hydrogel microcapsules for the healing of peptic ulcers

Rashad M. Kaoud¹, Mustafa Hasan Alwan¹, Mohammed Amran², Hayder Adnan Fawzi³

¹ College of Pharmacy, Ashur University, Baghdad, Iraq
² Department of Pharmacy, Al-Manara College for Medical Sciences, Maysan, Iraq
³ Department of Pharmacy, Al-Mustafa University College, Baghdad, Iraq

Corresponding author: Hayder Adnan Fawzi (haider-pharm@almustafauniversity.edu.iq)

Received 5 January 2024 ♦ Accepted 21 April 2024 ♦ Published 18 July 2024


Abstract
Hydrogels have gained much focus as a gastro-retentive technology for drug delivery. The current study aimed to design an oral mucoadhesive sustained-release dosage form to lower peptic ulcer complications (PUC). Using the Box-Behnken statistical design, the preparation method was developed by incorporating pantoprazole sodium (PZS) into hydrogel microcapsules (HGMC). The PZS was incorporated into the HGMC via an ion gelation technique, with sodium alginate as the gelling agent, calcium chloride as the crosslinking agent, and chitosan as the agent for sustained release.

The optimized formulation of PZS-HGMC showed a diameter of 2.506 mm, a swelling rate of 838.2%, and an encapsulation efficiency of 93.8%. Scanning electron microscopy images revealed the microcapsules’ spherical shape. The in vitro release of the PZS from the HGMC after two hours in a simulated gastric fluid was 13.2±0.08%, compared with the apparent solubility of the pure PZS under the same conditions (95.24%±3.2%). After 24 hours, the percent of PZS released from the optimized formula was 69.84±2.4%, which indicates a sustained release pattern. The results from the in vivo study demonstrated improved healing of the induced ulcers in rats when treated with the PZS-HGMC formulation as compared to the standard PZS therapy; therefore, the obtained mucoadhesive HGMC was considered a potential drug delivery strategy for PUC therapy.

Keywords
anti-ulcerogenic effect, Box-Behnken design, histopathological analysis, in vitro release

Introduction
A peptic ulcer is defined as a disruption in the mucosal lining of the gastrointestinal system, specifically in the stomach and upper part of the small intestine, caused by the release of acid or pepsin (Lanas and Chan 2017). Moreover, peptic ulceration penetrates the mucosa section, causing mucosal lesions and leading to digestive tract inflammation (Najm 2011; Lanas and Chan 2017). The management of peptic ulcers involves alleviating pain, promoting ulcer recovery, and averting potential sequels (Yuan et al. 2006). The availability of histamine (H2)-receptor antagonists and proton pump inhibitors (PPIs) broadens the treatment options for peptic ulcers (Yuan et al. 2006). Peptic ulcer complications (PUC) are usually treated with proton pump inhibitors (PPIs) over long periods of time (Khan and Howden 2018).
Pantoprazole sodium (PZS) is an effective PPI; it acts by irreversibly binding the parietal cells’ proton pump, which will hinder the main source of acid production in the stomach (Yu et al. 2017). PZS is a powerful tool when treating PUC and reflux esophagitis. Because PZS inhibits the hepatic microsomal P-450 monoxygenase pathway, medicines metabolized by this enzyme may acquire a longer serum half-life on simultaneous intake (Shin and Sachs 2008).

PZS possesses excellent permeability, solubility, and absolute bioavailability (77%) (Pue et al. 1993), oral bioavailability (80%–85%) (Pue et al. 1993), and a half-life of 1.0 hour. In addition, it can be given both orally and intravenously (Joseph et al. 2015). PZS is quickly absorbed and strongly protein-bound (98%). Maximal absorption occurs 2.5 hours after a single or multiple oral delivery (Joseph et al. 2015). Due to a rise in drug absorption when intragastric acidity lowers, the bioavailability of PZS rises with repeated doses up to around four days (Bigoniya et al. 2011).

Currently, PZS is available in such standard-approved formulations as tablets (EC polymer: methacrylic acid–ethyl acrylate copolymer (1:1) and controlcoated control), oral suspension (granules, enteric-coated polymer (methacrylic acid copolymer), and powder for solutions for injections (such as sodium hydroxide) (Srebro et al. 2022). In addition, other formulations still lacking official approval are the nanoprecipitation method (Nasef et al. 2017; Sheikh and Asati 2022), microparticles (Comoglu et al. 2008; Rafﬁn et al. 2008; Dhurke et al. 2013; Raj et al. 2015; Hamzah and Kassab 2024), enteric-coated minitablets (Szczepanska and Szniadowska 2019), enteric-coated pellets (Han et al. 2018), sustained release floating tablets (Reddy et al. 2018), hydrogel (Gupta and Shivakumar 2009; Taher et al. 2018; Sudhakaran et al. 2021), and the sustained release mucoadhesive gastroretentive system (Reddy and Jalajakshi 2018). These formulations were developed to address the various issues with the oral administration of this drug, including premature activation in the stomach since its absorption occurs in the duodenum (Shin and Sachs 2008) and increasing its duration of action (Srebro et al. 2022).

PUC can be treated in several ways, including using mucoadhesive HGMC drug delivery systems. HGMC have been studied as a potential gastroprotective dosage form because of their capacity to increase the bioavailability of PZS when taken orally by serving as a sustained-release dosage form (Gadge et al. 2019).

This study aims to formulate an oral mucoadhesive sustained-release dosage form containing pantoprazole sodium hydrogel microcapsules (PZS–HGMC) using the Box-Behnken design and then undergo characterization studies, an in vivo study (including histopathological examination), and an in vitro release study for the optimized PZS–HGMC formula.

**Materials and methods**

**Materials**

Pantoprazole sodium, sodium alginate, and chitosan were gifted by Al-Hikma Pharmaceuticals (Cairo, Egypt).

Hydrochloric acid (HCl) and calcium chloride (anhydrous fine GRG 90%) were purchased from the Al-Nasr Company for Pharmaceuticals (Cairo, Egypt). Generally, all the chemicals used were of analytical grade.

**Optimization of formulation variables**

The Box-Behnken statistical design with three factors, three levels, and 15 runs was chosen for the optimization analysis. Theoretically, the experimental design consists of points at the midpoint of each edge and the replicated center point of the multi-dimensional cube.

The dependent and independent variables in the experimental design of the microcapsules (MC) formulated by sodium alginate (SAT) and coated with chitosan (CTN) are presented in Table 1. Using the software Design Expert® (Version 7.0.0, Stat-Ease Inc., Minneapolis, MN, USA) and Minitab® 17.1.0, the following equation (quadratic model) was applied for designing the different formulas:

\[
Y_0 = b_0 + b_1X_1 + b_2X_2 + b_3X_3 + b_{11}X_1^2 + b_{22}X_2^2 + b_{33}X_3^2 + b_{12}X_1X_2 + b_{13}X_1X_3 + b_{23}X_2X_3
\]

\(Y_0\) is the dependent variable; \(b_0\) is an intercept; \(b_1\) to \(b_{33}\) are regression coefficients computed from the observed experimental values of \(Y\); and \(X_1, X_2,\) and \(X_3\) are the coded levels of independent variables. \(X_1X_2\) and \(X_2\) (\(i = 1, 2,\) or 3) represent the interaction and quadratic terms, respectively.

The primary constituents of the PZS-HGMC include PZS (20 mg), SAT, CTN, and calcium chloride (CaCl₂). These choices were made based on the initial experiments for the formulation of PZS-HGMC. The experimental design investigated the connection between the independent variables and their responses and interactions in an effective model. It involved three variables and three responses. While the independent variables were the concentration of SAT (\(X_1\)), the concentration of CaCl₂ (\(X_2\)), and the concentration of CTN (\(X_3\)), the measured dependent variables were particle diameter (\(Y_1\)), swelling degree (\(Y_2\)), and encapsulation efficiency (\(Y_3\)), as represented in Table 1.

**Table 1.** Independent and dependent variables applied in a Box-Behnken design.

<table>
<thead>
<tr>
<th>Factors</th>
<th>Independent variables</th>
<th>Low (+1)</th>
<th>Medium (0)</th>
<th>High (+3)</th>
</tr>
</thead>
<tbody>
<tr>
<td>(X_1)</td>
<td>Sodium Alginate (SAT)</td>
<td>%</td>
<td>1</td>
<td>2</td>
</tr>
<tr>
<td>(X_2)</td>
<td>Calcium Chloride (CaCl₂)</td>
<td>%</td>
<td>2</td>
<td>3</td>
</tr>
<tr>
<td>(X_3)</td>
<td>Chitosan (CTN)</td>
<td>%</td>
<td>0.1</td>
<td>0.3</td>
</tr>
<tr>
<td>Response</td>
<td>Particle Diameter</td>
<td>mm</td>
<td></td>
<td></td>
</tr>
<tr>
<td>(Y_1)</td>
<td>Swelling (SW%)</td>
<td>%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>(Y_2)</td>
<td>Encapsulation Efficiency (EE%)</td>
<td>%</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Preparation of PZS-HGMC**

The pantoprazole-loaded hydrogel microcapsules of alginate core and chitosan coating were prepared using the ion gelation method with some modifications (Ramos et al. 2018; Karakas et al. 2022; Padhmavathi et al. 2023).
As a first stage of formulation, SAT (1%–3% w/v) was dissolved in deionized water (20 mL) and stirred (900 rpm) at 25 °C. Then PZS 20 mg was dissolved in deionized water (10 mL) as the first solution. The second solution consisted of CTN (0.1%–0.5%) and CaCl2 (2%–4%) dissolved in a 1% v/v acetic acid solution, which was used as a coagulation fluid. The first solution was molded into a second homogenous solution with 0.1 N HCl, and the pH was adjusted to 5±0.1. A 1 mL/min pumping rate was used to keep the combined flow constant. After being stirred in the fluid for 20 minutes, PZS-HGMG was formulated. The PZS-HGMG were filtered, washed, and dried at 25±0.5 °C (Gioumouzouzis et al. 2018; Rostami 2020).

Optimization employing Box-Behnken design

The optimized formula was chosen according to the response to the desirability of variables (by maximizing particle diameter, swelling, and encapsulation efficiency). Physicochemical, in vitro, and in vivo analyses were conducted for the optimized formula.

It was validated statistically by constructing quadratic equations for the diameter of the response, SW% studies, and the EE% (Y1, Y2, and Y3), respectively.

Characteristics of the PZS-HGMG

Microcapsule diameter analysis

The PZS-HGMG were measured for diameter with a micrometer screw gauge, and the mean was then calculated (Zeeb et al. 2015).

Swelling experiments (SW%)  

The SW% of the HGMG was investigated via the immersing method (Anal and Stevens 2005) in detail. The SW study was conducted in a water bath shaker at 37±0.5 °C. Previously weighted HGMG were immersed in 0.1N HCl for two hours, resulting in the HGMG swelling. The swollen HGMG were wiped with filter paper to eliminate excessive buffer and then weighed. All significant shifts in the weight were recorded. The SW% was calculated by the following formula (Taher et al. 2019):

\[
\text{SW\%} = \frac{\text{Weight of swollen MCs} - \text{Weight of dry MCs}}{\text{Weight of dry MCs}} \times 100
\]

Encapsulation efficiency (EE%)

The drug content of the PZS-HGMG was directly measured. The PZS-HGMG (200 mg) was carefully weighed and crushed. The PZS-HGMG were mixed with deionized water (10 mL) for a full day at 25±0.5 °C. Then, the solution was filtered through a nano-filter syringe. The PZs concentration was detected spectrophotometrically using the UV-visible spectrophotometer (Shimadzu, Japan) at 283 nm. The EE% was detected using the following equation (Umaredkar et al. 2020):

\[
(\%\text{EE}) = \frac{\text{RA}}{\text{TA}} \times 100
\]

RA and TA are the resulting and theoretical amounts of PZS found in the PZS-HGMG, respectively. The results were repeated in triplicate.

SEM analysis

The morphologies and surface of the PZS-HGMG were investigated using SEM (Agilent 8500 FE, Japan) (Thanos et al. 2006). PZS-HGMG samples were covered with gold and photographed at a voltage of 30 kV before being placed on aluminum stubs for examination.

FTIR analysis for an optimized formula

Before submitting samples for FTIR evaluation, a pestle and mortar were used to reduce the PZS-HGMG to a powder. The FTIR probe examined the sample (JASCO FTIR Model 6600, Tokyo, Japan). The range was selected from 400 to 4000 cm\(^{-1}\) with 95% transmittance. Interactions can be detected, and functional group alterations can be identified using FTIR spectral analysis (FTIR spectrophotometer at a scanning number of 8 with the KBr sampling method) (Moghaddam et al. 2015).

DSC studies for an optimized formula

Some differential scanning calorimetry (DSC) studies were applied using DSC 60 TASYS Software (Shimadzu, Japan). The dry MCs used in the DSC trial varied from 3 to 7 mg. The sample was analyzed in a nitrogen flow with a 25–300 °C temperature, and the scan rate was 10 °C/min. The DSC detects crystallinity changes, melting points, and drug-excipient-adsorbent interactions (Honary et al. 2009).

In vitro drug release

The PZS release experiment used a USP apparatus type II (Copaly, United Kingdom) at 100 rpm and 37 °C. Then 20 mg of PZS-HGMG and PURE PZS were placed in hard gelatin capsules, and then the capsules were placed in 0.1N HCl (pH 1.2) to simulate the stomach environment over 24 hours. At each of the 24-hour intervals (10 intervals), 5 mL aliquots were removed and refilled with fresh dissolution media. The PZS concentration of each sample was determined at 283 nm spectrophotometrically (Shimadzu, Japan). The test was conducted in triplicate (Heikal et al. 2023).

In vivo anti-ulcerogenic study

The in vivo study was prepared following the ARRIVE Guidelines 2.0. Male Wistar rats (weighted around 180–200 g and ages 3–5 months) were received from the animal facility in the Pharmacy Department at Ashur University College. They were maintained at 25 °C and a light/dark cycle (12 hours light and 12 hours dark). The animals received commercial pellet feed and had free access to water. They were acclimated for 10 days before starting the experiment at the same center where the rats were obtained.

For sample size computation, the program G Power was utilized (Faul et al. 2007) based on Cohen’s principles.
(Charan and Kantharia 2013). The groupings were constructed randomly using a table of random integers. The mice were systematically allocated into properly marked boxes and individually identified with tail tags to mitigate the occurrence of misinterpretation (Festing 2006).

The study modules employed a randomized block design. The mice were categorized into five distinct blocks. Block one (G1) received their treatment plan. Then, in order in subsequent weeks, Block two (G2), Block three (G3), Block four (G4), and Block five (G5) commenced their respective treatments. Details of the animal allocation and drug dosing are illustrated in Table 2.

Table 2. Animal allocation for each group.

<table>
<thead>
<tr>
<th>Group</th>
<th>Indomethacin*</th>
<th>Drug received</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>G1</td>
<td>Did not receive</td>
<td>normal saline by gastric gavage</td>
<td>15 days</td>
</tr>
<tr>
<td>G2 (Bhattacharya et al. 2007; Sabiu et al. 2015)</td>
<td>Received</td>
<td>normal saline by gastric gavage</td>
<td>15 days</td>
</tr>
<tr>
<td>G3</td>
<td>Received</td>
<td>blank HGMC by gastric gavage</td>
<td>15 days</td>
</tr>
<tr>
<td>G4 (Xie et al. 2005)</td>
<td>Received</td>
<td>PZS pure (20 mg/kg) by gastric gavage</td>
<td>15 days</td>
</tr>
<tr>
<td>G5 (Xie et al. 2005)</td>
<td>Received</td>
<td>PZS-HGMC optimized formula (20 mg/kg) by gastric gavage</td>
<td>15 days</td>
</tr>
</tbody>
</table>

* Indomethacin: single dose of 30 mg/kg/day of IMN orally by gastric gavage. Each set was conducted in triplicate.

Induction of ulcers by indomethacin (IMN) was done (induction of gastric ulcers was done following previous studies) (Bhattacharya et al. 2007; Sabiu et al. 2015). The rats were given a single oral dose of IMN 1% sodium carboxymethylcellulose (CMC) (30 mg/kg body weight as a 2 ml solution), then they fasted for 24 hours, but they were allowed free access to water during this period.

In each group, the rats received the optimized formula once per day for 15 days. On the 16th day, all animals had a period of fasting lasting 10 hours. Subsequently, they were subjected to intraperitoneal (IP) anesthesia with a dosage of 80 mg/kg of ketamine (Ketanest 10%, Alfasan Nederland BV, Holland) and 10 mg/kg of xylazine (XYL-M2, VMD Livestock Pharma, Belgium). After undergoing complete anesthesia, the rats were euthanized using carbon dioxide (Underwood and Anthony 2020; Yaribeygi et al. 2023).

The stomachs of the rats were extracted and macroscopically evaluated for bleeding ulcers. The number and intensity of lesions per piece of gastric tissue were recorded microscopically. Lesions were assessed visually after opening the stomach, cleansing with ice-cold saline, and coating with filter paper (El-Deen et al. 2016).

**Histological assessment of rats’ gastric tissues**

The pieces of gastric tissue were preserved by immersion in 10% formalin and subsequent fixation in paraffin. Pieces of 5–6 µm thickness were colored with hematoxylin and eosin. The Sydney system was applied to assess microscopic changes in the gastric mucosa, including chronic lesions, dropout gland (atrophy) regions, and intestinal metaplasia (Dixon et al. 1996).

**Ethical approval**

Following CPCSEA regulations, the Institutional Animal Ethics Committee authorized the experimental protocols for research project number RP62 (date: 2 December 2022).

**Statistical analysis**

Experimental results are the mean±standard deviation (SD). The significance of differences was tested by analyzing variance (ANOVA). Differences were considered statistically significant at P ≤ 0.05.

**Results and discussion**

**Formulation and optimization using a Box-Behnken design**

Realizing the complexity of producing pharmaceutical formulations is made easier by the numerous benefits and the adaptability of the design. Several independent parameters govern the number of experiments required, whereas the responses for every trial are established and the multiple regression analysis is performed.

The current study employs a straightforward design with just three independent variables across three distinct levels of experimentation. All batches of the formulations were made as planned and tested for various responses. Using ANOVA (Analysis of Variance), the present study investigated each variable alone and interacted with the other responses to improve the outcomes. Using Design Expert® software and an ANOVA analysis, it produced 15 different formulations. It validated them statistically by constructing quadratic equations for the diameter of the response, SW% studies, and the EE% (Y1, Y2, and Y3), respectively, as illustrated by Table 3. The Box-Behnken Design was used, and the results were analyzed and proved using a significant coefficient with R² values across the entire region of experimentation. In addition, optimum checkpoint formulations were generated and analyzed to determine the optimized formula for the given experimental domain and Box-Behnken design equations.

**Diameter**

The resulting PZS-HGMC had diameters ranging from 1.3 to 2.5 mm by vernier caliper (Gulia et al. 2023), as displayed in Table 3.

**Swelling (%)**

Table 3 illustrates the swelling behavior of the PZS-HGMC at pH 1.2; the obtained SW% ranges from 410.0% to 840.0%.
The PZS-HGMG showed swelling, resulting in MC with a small amount of SAT bursting after two hours of testing. The Na\(^+\) ion in the used buffer and the Ca\(^{2+}\) ion in the cavity of Ca-alginate microcapsules are involved in the ion exchange mechanism (Elnashar et al. 2010). One possible cause of swelling involves the exposure of the dry PZS-HGMG to water, and the hydrophilic SAT and CTN groups caused them to swell (Khan et al. 2023).

**Drug encapsulation efficiency (EE%)**

The EE% was 87.0 to 94.0%; the greater EE% of the SAT–CTN microcapsules may be attributed to the more porous structure (Dhurke et al. 2013). Since Ca\(^{2+}\) and -NH\(_3^+\) of CTN compete, they can react with -COO– of SAT (Akyuz et al. 2017). The estimated values of EE are illustrated in Table 3.

### Development of the optimized model

The optimized PZS-HMG formula was developed using the indicated concentrations of variables from an overlay plot to ensure the model's accuracy. The effect of changing the concentrations of CaCl\(_2\), SAT, and CTN on response parameters (PZ, SW%, and EE%) was examined. The desirability of the optimized formula in this experiment would have maximum EE%, SW%, and PZ in the range.

#### Particle size (PS)

By fixing the effects of one parameter, one can examine the effects of the other two parameters with PS; thus, by holding the CTN concentration constant, SAT has a direct relationship with PS, and CaCl\(_2\) did not affect PS (Fig. 1A).

By holding the CaCl\(_2\) concentration constant, PS appeared to be directly associated with SAT, while CTN did not affect PS (Fig. 1B).

By holding the SAT concentration constant, both CTN and CaCl\(_2\) have a direct relationship with PS (Fig. 1C).

The overall adjusted R\(^2\) of the model was 99.11%, with SAT showing 84.75% contribution of the final model (p-value < 0.001), with SAT (r = 0.5, p-value < 0.001), CaCl\(_2\) (r = -0.0625, p-value = 0.006), SAT*SAT (r = -0.2, p-value < 0.001), CaCl\(_2^*\)CaCl\(_2\) (r = 0.175, p-value < 0.001), and CTN (r = -0.0625, p-value = 0.006).

### Table 3. Experimental design for the formulations of PZS-HG-MC using a Box-Behnken design.

<table>
<thead>
<tr>
<th>Run</th>
<th>SAT (%)</th>
<th>CaCl(_2) (%)</th>
<th>CTN (%)</th>
<th>Diameter (mm)</th>
<th>Swelling (SW%)</th>
<th>EE% (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>F1</td>
<td>-1</td>
<td>-1</td>
<td>0</td>
<td>1.0</td>
<td>2.0</td>
<td>0.3</td>
</tr>
<tr>
<td>F2</td>
<td>1</td>
<td>-1</td>
<td>0</td>
<td>3.0</td>
<td>2.0</td>
<td>0.3</td>
</tr>
<tr>
<td>F3</td>
<td>-1</td>
<td>1</td>
<td>0</td>
<td>1.0</td>
<td>4.0</td>
<td>0.3</td>
</tr>
<tr>
<td>F4</td>
<td>1</td>
<td>1</td>
<td>0</td>
<td>3.0</td>
<td>4.0</td>
<td>0.3</td>
</tr>
<tr>
<td>F5</td>
<td>-1</td>
<td>0</td>
<td>-1</td>
<td>1.0</td>
<td>3.0</td>
<td>0.1</td>
</tr>
<tr>
<td>F6</td>
<td>1</td>
<td>0</td>
<td>-1</td>
<td>3.0</td>
<td>3.0</td>
<td>0.1</td>
</tr>
<tr>
<td>F7</td>
<td>-1</td>
<td>0</td>
<td>1</td>
<td>1.0</td>
<td>3.0</td>
<td>0.5</td>
</tr>
<tr>
<td>F8</td>
<td>1</td>
<td>0</td>
<td>1</td>
<td>3.0</td>
<td>3.0</td>
<td>0.5</td>
</tr>
<tr>
<td>F9</td>
<td>0</td>
<td>-1</td>
<td>-1</td>
<td>2.0</td>
<td>2.0</td>
<td>0.1</td>
</tr>
<tr>
<td>F10</td>
<td>0</td>
<td>1</td>
<td>-1</td>
<td>2.0</td>
<td>4.0</td>
<td>0.1</td>
</tr>
<tr>
<td>F11</td>
<td>0</td>
<td>-1</td>
<td>1</td>
<td>2.0</td>
<td>2.0</td>
<td>0.5</td>
</tr>
<tr>
<td>F12</td>
<td>0</td>
<td>1</td>
<td>1</td>
<td>2.0</td>
<td>4.0</td>
<td>0.5</td>
</tr>
<tr>
<td>F13</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>2.0</td>
<td>3.0</td>
<td>0.3</td>
</tr>
<tr>
<td>F14</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>2.0</td>
<td>3.0</td>
<td>0.3</td>
</tr>
<tr>
<td>F15</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>2.0</td>
<td>3.0</td>
<td>0.3</td>
</tr>
</tbody>
</table>

Data presented as mean±SD, n = 3.

Figure 1. Response surface graphs show variables' effects on (A, B, C) particle size.
and SAT*CaCl₂ (r = 0.075, p-value = 0.012) are the significant coefficients in the final model:

\[
\text{Particle size (mm)} = 2.787 + 1.038 \text{Alginate} - 1.338 \text{CaCl₂} - 1.437 \text{Chitosan} - 0.2000 \text{Alginate} \times \text{Alginate} + 0.1750 \text{CaCl₂} \times \text{CaCl₂} + 0.625 \text{Chitosan} \times \text{CaCl₂} + 0.0750 \text{Alginate} \times \text{Chitosan} + 0.1250 \text{Alginate} \times \text{CaCl₂} + 0.2500 \text{CaCl₂} \times \text{Chitosan}
\]

**Swelling (%)**

By fixing the effects of one parameter, one can examine the effects of the other two parameters with SW%; thus, by holding the CTN concentration constant, SAT has a direct relationship with SW%, and CaCl₂ did not affect SW% (Fig. 2A).

By holding the CaCl₂ concentration constant, SAT and CaCl₂ have a direct relationship with SW% (Fig. 2B).

By holding the concentration of SAT constant, both CTN and CaCl₂ have a direct relationship with SW% (Fig. 2C).

The overall adjusted R² of the model was 97.0%, with SAT showing a 78.92% contribution to the final model (p-value < 0.001), with SAT (r = 160.63, p-value < 0.001), and SAT*SAT (r = 108.1, p-value < 0.001) as the significant coefficients in the final model:

\[
\text{Swelling (\%)} = 509 - 313.1 \text{Alginate} + 113.1 \text{CaCl₂} - 378 \text{Chitosan} + 108.1 \text{Alginate} \times \text{Alginate} - 16.9 \text{CaCl₂} \times \text{CaCl₂} + 422 \text{Chitosan} \times \text{Chitosan} + 3.8 \text{Alginate} \times \text{CaCl₂} + 100.0 \text{Alginate} \times \text{Chitosan} - 0.0 \text{CaCl₂} \times \text{Chitosan}
\]

**Encapsulation efficacy (%) (EE%)**

By fixing the effects of one parameter, one can examine the effects of the other two parameters with EE%. By holding the CTN concentration constant, SAT and CaCl₂ have a direct relationship with EE% (Fig. 3A).

By holding the CaCl₂ concentration constant, EE% appeared to be directly associated with SAT and CTN (Fig. 3B).

By holding the concentration of SAT constant, both CTN and CaCl₂ have a direct relationship with EE% (Fig. 3C).

The overall adjusted R² of the model was 87.13%, with SAT showing an 82.77% contribution to the final model (p-value < 0.001), with SAT (r = 2.25, p-value < 0.001), and CaCl₂ (r = 0.625, p-value = 0.046) as the significant coefficients in the final model:

\[
\text{Encapsulation efficacy (\%)} = 82.75 + 1.88 \text{Alginate} + 2.62 \text{CaCl₂} - 4.38 \text{Chitosan} - 0.000 \text{Alginate} \times \text{Alginate} - 0.250 \text{CaCl₂} \times \text{CaCl₂} - 6.25 \text{Chitosan} \times \text{Chitosan} - 0.250 \text{Alginate} \times \text{CaCl₂} + 3.75 \text{Alginate} \times \text{Chitosan} + 0.00 \text{CaCl₂} \times \text{Chitosan}
\]

**Effect of SAT**

The concentration of SAT increased, and the diameter increased (Fig. 1A, B). This result is compatible with the outcomes of (Patil et al. 2012). The model graphs indicated that SAT significantly impacts the SW of various formulations (Fig. 2A, B). When the content of SAT grew, the formulations swelled, as represented by (Swain et al. 2014), who discovered a relation between the rising

---

**Figure 2.** Response surface graphs show variables’ effects on (A, B, C) swelling%.
swelling and diameter. Model graphs demonstrated that SAT significantly impacts the EE% of different formulas. Fig. 3A, B show that, as the content of SAT increased, the EE% of different formulae also increased. This is consistent with the results of (Babu et al. 2011), who found the same outcomes: when the SAT was raised, the EE% was significantly raised in different formulas.

**Effect of CaCl\textsubscript{2}**

CaCl\textsubscript{2} change, when considered in terms of change in SAT, showed no significant effect, which indicates SAT has more effect on the PZ at all concentrations of CaCl\textsubscript{2}; however, the effect on CaCl\textsubscript{2} change when examined against the change in CTN showed variability, in which a larger PS was achieved with low concentrations of CaCl\textsubscript{2} and higher concentrations of CTN and the lowest PS was achieved with medium concentrations of CaCl\textsubscript{2} and the lowest concentrations of CTN. It is evident from the model graphs displayed in Fig. 1A, C that, with increasing CaCl\textsubscript{2} concentration, the response surface shifts from a higher diameter value to a smaller one.

Dissolution of the PZS-HGMG formulated in a low CaCl\textsubscript{2} solution occurred sooner than in PZS-HGMG formulated in CaCl\textsubscript{2} solutions of higher concentrations, and the maximum SW ratios rose with the increase in CaCl\textsubscript{2} concentration at pH 1.2. The concentration of Ca\textsuperscript{2+} during the formulation of PZS-HGMG may improve their cross-linking density. This observation is consistent with those of (Laelorspoen et al. 2014).

It is blatantly obvious in Fig. 1G, I that the EE% was raised when the CaCl\textsubscript{2} content was raised due to the cross-linking reaction being favored (Ghumman et al. 2018).

**Effect of CTN**

As CTN concentration increases, the resulting formulation’s diameters rise (Wang et al. 2017). A thicker CTN layer may increase the size of the formulations. This trend lines up with a rise in the mean diameters of the PZS-HGMG, as shown in Fig. 1C.

The SW% index grew dramatically with rising CTN concentrations at pH 1.2. The raised concentration of CTN led to a raised SW% of different formulae (Fig. 2C). This observation is consistent with previous studies (Sinha et al. 2018).

The impacts of CTN concentration on the diameter and EE% of different formulas may explain why a reduction in CTN concentration led to a decline in EE%. The results are shown in Fig. 2C and are consistent with another study (Mi et al. 2013). By elevating the concentration of CTN in the coagulation solution, the density of the resulting membrane is increased as more SAT-CTN ionic interactions are created, resulting in a less perforated gel formation and a higher EE%; this might be because the medicine is less likely to escape from the PZS-HGMG during encapsulation.

**Selection of the optimized formula**

The optimized formula was chosen by the numerical optimization of Design Expert® software based on the desirability factor’s proximity to 1 (Fig. 4). Variable parameters were set in a range. The optimized formula in this experiment would have maximum EE%, SW%, and PZ in the range. The predicted SAT (X1 = 3% w/v), CaCl\textsubscript{2}...
(X2 = 3.818% w/v), and polymer CTN (X3 = 0.5%) were acquired, and this was selected as the optimized formula with a desirability of 0.9814.

These values predict a 2.506 mm diameter, 838.249% SW, and 93.7645% EE. Further characterization confirmed that the optimized formula was valid and determined to be within acceptable ranges.

Morphology of an optimized formula

Fig. 5A shows SEM micrographs of blank HGMC, which were smaller and smoother than the PZS-HGMC optimized formula (Fig. 5B). As can be seen, the surface morphology of drug-loaded MC was regular. The SEM results provided by (Thakral et al. 2010) also displayed similar observations. Fig. 5B shows that the PZS-loaded microcapsules had a spherical appearance.

3.5 FTIR analysis

Infrared spectroscopic analysis for PZS, SAT, CTN, physical mixture HGMC, and the PZS-HGMC optimized formula is shown in Fig. 4. From the data obtained by FTIR (Fig. 6), there are no significant chemical changes between the pure PZS and PZS-HGMC optimized formulas. A stretching endothermic peak marks the characteristic absorption of PZS at 2968.26 cm⁻¹, representing the presence of the C-H group. Another stretching peak appeared at 1647.96 cm⁻¹, which is distinctive to the C = N group. The aromatic ether stretching peak is at 1188.71 cm⁻¹, and the bending peak of the C = C group is displayed at 810.50 cm⁻¹. The FTIR spectrum for the optimized formula exhibited the same peaks as pure PZS at comparable wavelengths, which indicates chemical compatibility between PZS and optimized formula components (Kumar et al. 2016; Nasef et al. 2017).

DSC for optimized formula

The DSC thermograms for PZS, SAT, CTN, the optimized formula physical mixture, and the PZS-HGMC optimized formula are shown in Fig. 6. An endothermic peak at 141.28 °C was observed for pure PZS, corresponding to its melting point. DSC analysis further verifies that the formulation did not involve any drug-polymer interactions. The optimized PZS-HGMC formulation exhibited an endothermic peak at 201.18 °C, characteristic of the polymer matrix. The drug appears to undergo amorphization. The trapping of PZS in the polymer matrix may explain the findings (Abbas and Hanif 2018).

In vitro release and kinetic analysis

Both the free PZS (R²adj = 0.985) and PZS-HGMC (R²adj = 0.935) releases followed first-order kinetics (DSSolver 1.0 performed analysis). Fig. 7 shows the cumulative release profile (smother line used). In the case of the free PZS, 95.24±3.2% of PZS was released in the first two hours. This case is unacceptable for drugs that must be sustained and released in the stomach. Fig. 8 shows the drug released from the PZS-HGMC optimized formula in 0.1N HCl (pH = 1.2) fluid. The initial release of drugs from the PZS-HGMG was low. Only 13.21±0.08% of PZS was released after two hours and 40.8±1.2% of PZS after 12 hours; however, after 24 hours, approximately 69.84±2.4% of PZS had been released (Gulia et al. 2023). The film's solidity is compromised by ionization, allowing the PZS to leak out. CTN was dissolved at a pH of 1.2, and after SW and polymer matrix erosion, the PZS was liberated (Sohail et al. 2012).

In vivo treatment efficacy

Evaluation of gastric tissue macroscopic injuries

Macroscopic evaluation of the examined rats’ gastric tissues is shown in Fig. 8. The negative control group’s gastric tissues (Fig. 9A) exhibited healthy mucosa, minimal redness, and no bleeding or regions of hyperemia. On the other hand, the injured rat groups’ (G2 and G3) showed extensive damage to the stomach mucosa (Fig. 9B, C).

Figure 4. The Design Expert® program forecasted a 3D surface plot displaying the desirability value for optimized formulation.
Figure 5. SEM analysis: A. Blank (drug-unloaded) HGMG; B. PZS-HGMG.

Figure 6. FTIR spectra of A. PZS; B. SAT; C. CTN; D. PZS-HGMG physical mixture; E. PZS-HGMG formula.

Figure 7. DSC spectra of A. PZS; B. SAT; C. CTN; D. Optimized formula physical mixture; E. Optimized PZS-HGMG formula.
Figure 8. Cumulative drug release (%) of PZS capsule and PZS-HGMC formula in 0.1 N HCl.

Figure 9. The appearance of the mucosa in the stomachs of IMN-induced rats: A. Negative control group; B. Positive control group; C. Blank MC-treated group; D. Free PZS-treated group; E. PZS-HGMC-optimized formula-treated group.
When given orally (30 mg/kg), IMN caused severe bleeding sores, most of which were in the gastric glandular mucosa and very few, if any, in the antrum (Yusif et al. 2016). Most of the gastric body was discolored dark reddish from lesions, and the gastric mucosa was riddled with multiple ulcer regions of varying shapes and sizes. The gastric mucosa showed considerable hyperemia.

There were fewer stomach ulcers after administering free PZS to the rats (Fig. 9D). The lesions emerged as discrete lesions in the gastric mucosa, and the epithelial injuries were modest compared to those seen in erythematous control animals (Özgüney 2011). The incision was not observed in any of the medicated rat groups.

On the other hand, medication with a PZS-HGMC optimized formula (Fig. 9E) exhibited an almost typical stomach look, with only a little ulceration and no redness or bleeding. During the study, the rats in the medicated groups were healthier and behaved normally. The results showed that the medication of animals with PZS-HGMC provided more protection against PUC than medication with free PZS. This could be because the medicine is released slowly over time, retaining a potent concentration of the PZS for a longer period.

**Histopathological analysis**

The variations in the gastric tissues of the tested rat groups were confirmed through histopathological evaluation. Fig. 10 shows the histopathological analysis of various groups. The gastric histology of the control normal animals (Fig. 10A), which comprise the negative control group (G1), displays a typical glandular structure and function at the microscopic level.

![Figure 10](image)

**Figure 10.** Histological examination of gastric tissues from the INM-induced lesion pattern in rats: A. Normal group; B. INM-treated control group; C. Blank MC-treated group; D. Free PZS-treated group; E. PZS-HGMC-optimized formula-treated group.
Eccentric nuclei and pale eosinophilic vacuoles in the cytoplasm characterize the parietal cells that make up the top half of the stomach. On the contrary, the INM-mediated control group (G2) (Fig. 10B) shows a prominent inflammatory response characterized by subepithelial edema. The heavily muscled coat was broadened and somewhat hyalinized, and the subepithelial blood arteries were clogged with plaque.

These findings demonstrated the chronic inflammation and acute stage of the lesion. The findings also showed the gastric tissue to be highly inflamed for the INM-mediated group (G3) receiving the blank MC (Fig. 10C). The gastric tissue of (G4), receiving the free PZS, exhibited moderate lesions (Fig. 10D). In (G5), receiving the PZS-HGMC optimized formula (Fig. 10E), the rats had the greatest morphological preservation. They exhibited regular epithelial and lymphatic organization, distribution, and excellent tissue morphology.

**Conclusion**

In the present study, the oral treatment of IMN-induced PUC in experimental rats with the optimized PZS-HGMC formula for 15 successive days significantly accelerated the recovery of induced PUC compared to the oral treatment with free PZS. SEM photographs showed spherical, smooth surfaces for PZS-HGGM. The FTIR study confirmed the interaction between PZS molecules and the CTN network. DSC showed the dispersion of PZS in the PZS-HGGM network. The effect of different independent variables on diameter, SW%, and EE% was studied for different formulae.

The PZS-HGMC optimized formula has been further examined. The in vitro release of the optimized formula was compared with free PZS in acidic media for 24 hours. The results indicated the release of 95.24±3.2% of free PZS in the first two hours, compared to 13.21±0.08% of the optimized formula. After 24 hours, approximately 69.84±2.4% of PZS was released from the optimized formula. In conclusion, the PZS-HGMC optimized formula exhibited a sustained release effect and improved the healing of PUC compared to free PZS.

**Funding**

The authors declare that no funds, grants, or other support were received during the preparation of this manuscript.

**Competing interests**

The authors have no relevant financial or non-financial interests to disclose.

**Consent to participate**

Not applicable.

**References**


